Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel polymer micelles plus bevacizumab in platinum-resistant recurrent ovarian, fallopian tube, and primary peritoneal cancer
ChiCTR2600134114Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 cohorts), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Sep 2024; status: recruiting.
02
Drugs
paclitaxelbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600134114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134114.